In a pancreatic cancer preclinical model, Ibrutinib (an inhibitor of Bruton’s tyrosine kinase) was used to reset M0 macrophages toward an M1-like phenotype that promoted CD8+ T cell cytotoxicity, and this approach is currently being evaluated in combination with checkpoint inhibitors [44]. The gene discussed is CD8A; the disease is pancreatic neoplasm.